Tom K Birkenhager
Overview
Explore the profile of Tom K Birkenhager including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
629
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loef D, Hoogendoorn A, Somers M, Mocking R, Scheepens D, Scheepstra K, et al.
Mol Psychiatry
. 2024 Oct;
PMID: 39448805
Reliable predictors for electroconvulsive therapy (ECT) effectiveness would allow a more precise and personalized approach for the treatment of major depressive disorder (MDD). Prediction models were created using a priori...
2.
Spaan P, Verrijp T, Michielsen P, Birkenhager T, Hoogendijk W, Roza S
J Affect Disord
. 2024 Sep;
368:237-248.
PMID: 39265870
Background: The dexamethasone suppression test (DST), which measures HPA-axis functioning, is a potential biomarker for suicidal behavior. The current study aimed (a) to synthesize available knowledge on the association between...
3.
Birkenhager T, Heijnen W
Acta Psychiatr Scand
. 2024 Sep;
150(6):497-499.
PMID: 39227148
No abstract available.
4.
Ertman M, van der Valk Bouman E, Clephas P, Birkenhager T, Klimek M
J ECT
. 2024 Aug;
41(1):17-26.
PMID: 39105589
Postictal agitation (PIA) is an adverse effect of electroconvulsive therapy (ECT) and is known to predict other side effects of ECT, but inconsistencies in the literature remain regarding PIA prognostic...
5.
Ter Hark S, Coenen M, Vos C, Aarnoutse R, Nolen W, Birkenhager T, et al.
Transl Psychiatry
. 2024 Apr;
14(1):198.
PMID: 38671038
No abstract available.
6.
Ter Hark S, Coenen M, Vos C, Aarnoutse R, Nolen W, Birkenhager T, et al.
Transl Psychiatry
. 2024 Mar;
14(1):132.
PMID: 38431658
Psychotic depression is a severe and difficult-to-treat subtype of major depressive disorder for which higher rates of treatment-resistant depression were found. Studies have been performed aiming to predict treatment-resistant depression...
7.
Vos C, Birkenhager T, Nolen W, Van den Broek W, Ter Hark S, Schellekens A, et al.
J Clin Psychopharmacol
. 2023 Nov;
43(6):486-492.
PMID: 37930199
Background: Since insomnia and depression are interrelated, improved sleep early in antidepressant pharmacotherapy may predict a positive treatment outcome. We investigated whether early insomnia improvement (EII) predicted treatment outcome in...
8.
Van den Eynde V, Parker G, Ruhe H, Birkenhager T, Godet L, Shorter E, et al.
Psychopharmacol Bull
. 2023 Aug;
53(3):35-54.
PMID: 37601082
The first monoamine oxidase inhibitors (MAOIs) used for the treatment of depression in the 1950-60s were credited with treating severe melancholic depression (MeD) successfully and greatly reducing the need for...
9.
Rossano F, Caiazza C, Sobrino A, Solini N, Vellucci A, Zotti N, et al.
Eur Neuropsychopharmacol
. 2023 Apr;
72:60-78.
PMID: 37087864
Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. The present...
10.
Pluijms E, Vinther P, Kamperman A, Birkenhager T
Acta Psychiatr Scand
. 2023 Mar;
147(6):561-569.
PMID: 36938869
Objective: High relapse rates are observed after electroconvulsive therapy (ECT) for major depression. Identifying patients who are at increased risk for relapse to intensify their treatment regimen post-ECT might reduce...